Who are nebulized ketamine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Namenda, Felbatol, QUINIDINE, Methadone Hydrochloride, Ketamine + magnesium, Intravenous Ketamine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nebulized-ketamine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

nebulized ketamine — Competitive Intelligence Brief

nebulized ketamine (nebulized ketamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: anesthetic. Area: Pain management.

phase 3 anesthetic NMDA receptor Pain management Small molecule Live · refreshed every 30 min

Target snapshot

nebulized ketamine (nebulized ketamine) — Theresa Jacob, PhD, MPH. Nebulized ketamine works by blocking NMDA receptors in the brain, which can help reduce inflammation and pain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
nebulized ketamine TARGET	nebulized ketamine	Theresa Jacob, PhD, MPH	phase 3	anesthetic	NMDA receptor
Namenda	MEMANTINE	AbbVie	marketed	N-methyl-D-aspartate Receptor Antagonist	Glutamate NMDA receptor; GRIN1/GRIN2A	2003-01-01
Felbatol	FELBAMATE	Mylan Speciality Lp	marketed	Anti-epileptic Agent [EPC]	NMDA receptor-ionophore complex	1993-01-01
QUINIDINE	QUINIDINE		marketed		sigma-1 receptor, NMDA receptor, CYP2D6	1950-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
Ketamine + magnesium	Ketamine + magnesium	University of Chile	marketed	NMDA receptor antagonist combination	NMDA receptor
Intravenous Ketamine	Intravenous Ketamine	Rebecca Price	marketed	Dissociative anesthetic	NMDA receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (anesthetic class)

Theresa Jacob, PhD, MPH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). nebulized ketamine — Competitive Intelligence Brief. https://druglandscape.com/ci/nebulized-ketamine. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab